Nanoplasmonic immunosensor for the detection of SCG2, a candidate serum biomarker for the early diagnosis of neurodevelopmental disorder.

Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE

Original Publication: London : Nature Publishing Group, copyright 2011-

Biomarkers/*blood ; Biosensing Techniques/*methods ; Immunoassay/*methods ; Nanoparticles/*chemistry ; Neurodevelopmental Disorders/*diagnosis ; Neurons/*pathology ; Secretogranin II/*blood; Animals ; Case-Control Studies ; Child ; Early Diagnosis ; Hippocampus/metabolism ; Hippocampus/pathology ; Humans ; Neurodevelopmental Disorders/blood ; Neurons/metabolism ; Rats

The neural circuits of the infant brain are rapidly established near 6 months of age, but neurodevelopmental disorders can be diagnosed only at the age of 2-3 years using existing diagnostic methods. Early diagnosis is very important to alleviate life-long disability in patients through appropriate early intervention, and it is imperative to develop new diagnostic methods for early detection of neurodevelopmental disorders. We examined the serum level of secretogranin II (SCG2) in pediatric patients to evaluate its potential role as a biomarker for neurodevelopmental disorders. A plasmonic immunosensor performing an enzyme-linked immunosorbent assay (ELISA) on a gold nanodot array was developed to detect SCG2 in small volumes of serum. This nanoplasmonic immunosensor combined with tyramide signal amplification was highly sensitive to detect SCG2 in only 5 μL serum samples. The analysis using the nanoplasmonic immunosensor revealed higher serum SCG2 levels in pediatric patients with developmental delay than in the control group. Overexpression or knockdown of SCG2 in hippocampal neurons significantly attenuated dendritic arborization and synaptic formation. These results suggest that dysregulated SCG2 expression impairs neural development. In conclusion, we developed a highly sensitive nanoplasmonic immunosensor to detect serum SCG2, a candidate biomarker for the early diagnosis of neurodevelopmental disorders.
(© 2021. The Author(s).)

Erratum in: Sci Rep. 2021 Dec 16;11(1):24386. (PMID: 34916556)

Diagnostic and Statistical Manual of Mental Disorders: DSM-5. 5th ed. Arlington, VA. American Psychiatric Association. https://doi.org/10.1176/appi.books.9780890425596 (2013).
Savatt, J. M. & Myers, S. M. Genetic testing in neurodevelopmental disorders. Front. Pediatr. 9, 526779 (2021). (PMID: 33681094793379710.3389/fped.2021.526779)
Tărlungeanu, D. C. & Novarino, G. Genomics in neurodevelopmental disorders: An avenue to personalized medicine. Exp. Mol. Med. 50, 1–7 (2018). (PMID: 3008984010.1038/s12276-018-0129-7)
Yao, F. et al. Protein biomarkers of autism spectrum disorder identified by computational and experimental methods. Front. Psych. 12, 554621 (2021). (PMID: 10.3389/fpsyt.2021.554621)
Yasui, Y. A data-analytic strategy for protein biomarker discovery: Profiling of high-dimensional proteomic data for cancer detection. Biostatistics 4, 449–463 (2003). (PMID: 1292551110.1093/biostatistics/4.3.449)
Murtaza, N., Uy, J. & Singh, K. K. Emerging proteomic approaches to identify the underlying pathophysiology of neurodevelopmental and neurodegenerative disorders. Mol. Autism 11, 27 (2020). (PMID: 32317014717183910.1186/s13229-020-00334-5)
Iwase, K. et al. The secretogranin II gene is a signal integrator of glutamate and dopamine inputs. J. Neurochem. 128, 233–245 (2014). (PMID: 2411198410.1111/jnc.12467)
Kim, H. J. et al. REST regulates non–cell-autonomous neuronal differentiation and maturation of neural progenitor cells via secretogranin II. J. Neurosci. 35, 14872–14884 (2015). (PMID: 26538656463513410.1523/JNEUROSCI.4286-14.2015)
Mattsson, N. et al. Cerebrospinal fluid concentrations of peptides derived from chromogranin B and secretogranin II are decreased in multiple sclerosis. J. Neurochem. 103, 1932–1939 (2007). (PMID: 1795365510.1111/j.1471-4159.2007.04985.x)
Duits, F. H. et al. Synaptic proteins in CSF as potential novel biomarkers for prognosis in prodromal Alzheimer’s disease. Alzheimers. Res. Ther. 10, 5 (2018). (PMID: 29370833638907310.1186/s13195-017-0335-x)
Saylan, Y., Akgönüllü, S. & Denizli, A. Plasmonic sensors for monitoring biological and chemical threat agents. Biosensor 10, 142 (2020). (PMID: 10.3390/bios10100142)
de la Rica, R. & Stevens, M. M. Plasmonic ELISA for the ultrasensitive detection of disease biomarkers with the naked eye. Nat. Nanotechnol. 7, 821–824 (2012). (PMID: 2310393510.1038/nnano.2012.186)
Scott, M. et al. Plasmonic substrates for multiplexed protein microarrays with femtomolar sensitivity and broad dynamic range. Nat. Commun. 2, 466 (2012).
Li, M., Cushing, S. K. & Wu, N. Plasmon-enhanced optical sensors: A review. Analyst 140, 386 (2015). (PMID: 25365823427427110.1039/C4AN01079E)
Mayer, K. M. et al. A label-free immunoassay based upon localized surface plasmon resonance of gold nanorods. ACS Nano 2, 687–692 (2008). (PMID: 1920659910.1021/nn7003734)
Endo, T., Kerman, K., Nagatani, N., Takamura, Y. & Tamiya, E. Label-free detection of peptide nucleic acid-DNA hybridization using LSPR based optical biosensor. Anal. Chem. 77, 6976–6984 (2005). (PMID: 1625559810.1021/ac0513459)
Mock, J. J., Smith, D. R. & Schultz, S. Local refractive index dependence of plasmon resonance spectra from individual nanoparticles. Nano Lett. 3, 485–491 (2003). (PMID: 10.1021/nl0340475)
Raschke, G. et al. Biomolecular recognition based on single gold nanoparticle light scattering. Nano Lett. 3, 935–938 (2003). (PMID: 10.1021/nl034223+)
Park, J. H., Byun, J. Y., Jang, H., Hong, D. & Kim, M. G. A highly sensitive and widely adaptable plasmonic aptasensor using berberine for small-molecule detection. Biosens. Bioelectron. 97, 292–298 (2017). (PMID: 2861836510.1016/j.bios.2017.06.019)
Haes, A. J. & Van Duyne, R. P. A nanoscale optical biosensor: Sensitivity and selectivity of an approach based on the localized surface plasmon resonance spectroscopy of triangular silver nanoparticles. J. Am. Chem. Soc. 124, 10596–10604 (2002). (PMID: 1219776210.1021/ja020393x)
Jo, N., Lee, K. & Shin, Y. B. Enzyme-coupled nanoplasmonic biosensing of cancer markers in human serum. Biosens. Bioelectron. 81, 324–333 (2016). (PMID: 2698558510.1016/j.bios.2016.03.009)
Jo, N. & Shin, Y. B. Enhancing biosensing sensitivity of metal nanostructures through site selective binding. Sci. Rep. 10, 1024 (2020). (PMID: 31974422697845910.1038/s41598-020-57791-4)
Lee, S. W. et al. Highly sensitive biosensing using arrays of plasmonic Au nanodisks realized by nanoimprint lithography. ACS Nano 5, 897–904 (2011). (PMID: 2122248710.1021/nn102041m)
Faget, L. & Hnasko, T. S. Tyramide signal amplification for immunofluorescent enhancement. In: Hnasko R. (eds) ELISA. Methods in Molecular Biology, vol. 1318. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-2742-5_16 (2015).
Stack, E. C., Wang, C., Roman, K. A. & Hoyt, C. C. Multiplexed immunohistochemistry, imaging, and quantitation: A review, with an assessment of tyramide signal amplification, multispectral imaging and multiplex analysis. Methods 70, 46–58 (2014). (PMID: 2524272010.1016/j.ymeth.2014.08.016)
Akama, K., Shirai, K. & Suzuki, S. Droplet-Free digital enzyme-linked immunosorbent assay based on a tyramide signal amplification system. Anal. Chem. 88, 7123–7129 (2016). (PMID: 2732252510.1021/acs.analchem.6b01148)
Fu, C. et al. Catalyzed deposition of signal reporter for highly sensitive surface-enhanced Raman spectroscopy immunoassay based on tyramine signal amplification strategy. Anal. Chem. 90, 13159–13162 (2018). (PMID: 3026456110.1021/acs.analchem.8b02419)
Li, X., Chen, B., He, M., Xiao, G. & Hu, B. Gold nanoparticle labeling with tyramide signal amplification for highly sensitive detection of alpha fetoprotein in human serum by ICP-MS. Talanta 176, 40–46 (2018). (PMID: 2891776810.1016/j.talanta.2017.08.007)
Lim, S. H. et al. Synapse formation regulated by protein tyrosine phosphatase receptor T through interaction with cell adhesion molecules and Fyn. EMBO J. 28, 3564–3578 (2009). (PMID: 19816407278210010.1038/emboj.2009.289)
Lim, S. H. et al. Depression-like behaviors induced by defective PTPRT activity through dysregulated synaptic functions and neurogenesis. J. Cell Sci. 133, jcs243972 (2020). (PMID: 3293868410.1242/jcs.243972)
Schuurs-Hoeijmakers, J. H. et al. Identification of pathogenic gene variants in small families with intellectually disabled siblings by exome sequencing. J. Med. Genet. 50, 802–811 (2013). (PMID: 2412387610.1136/jmedgenet-2013-101644)
Quintela, I. et al. Copy number variation analysis of patients with intellectual disability from North-West Spain. Gene 626, 189–199 (2017). (PMID: 2850674810.1016/j.gene.2017.05.032)
Allen-Brady, K. et al. A high-density SNP genome-wide linkage scan in a large autism extended pedigree. Mol. Psychiat. 14, 590–600 (2009). (PMID: 10.1038/mp.2008.14)
Aston, C., Jiang, L. & Sokolov, B. P. Transcriptional profiling reveals evidence for signaling and oligodendroglial abnormalities in the temporal cortex from patients with major depressive disorder. Mol. Psychiat. 10, 309–322 (2005). (PMID: 10.1038/sj.mp.4001565)
Zablotsky, B. et al. Prevalence and trends of developmental disabilities among children in the United States: 2009–2017. Pediatrics 144, e20190811 (2019). (PMID: 3155857610.1542/peds.2019-0811)
Xu, D. J., Wei, L. Y., Li, H. F. & Zhang, W. Q. Serum levels of chromogranins and secretogranins correlate with the progress and severity of Parkinson’s disease. Kaohsiung J. Med. Sci. 35, 146–150 (2019). (PMID: 3088772410.1002/kjm2.12026)
Neul, J. L. et al. Metabolic signatures differentiate Rett syndrome from unaffected siblings. Front. Integr. Neurosci. 14, 7 (2020). (PMID: 32161522705237510.3389/fnint.2020.00007)
McLane, R. D. et al. Peripheral amyloid precursor protein derivative expression in fragile x syndrome. Front. Integr. Neurosci. 13, 49 (2019). (PMID: 31551722673399310.3389/fnint.2019.00049)
Sahin, M., Sweeney, J. & Jones, S. R. Biomarkers to enable therapeutics development in neurodevelopmental disorders. Front. Integr. Neurosci. 14, 616641 (2020). (PMID: 33262695768657510.3389/fnint.2020.616641)
Shyu, W. C. et al. Secretoneurin promotes neuroprotection and neuronal plasticity via the Jak2/Stat3 pathway in murine models of stroke. J. Clin. Invest. 118, 133–148 (2008). (PMID: 1807996610.1172/JCI32723)
Kennedy, M. B. Synaptic signaling in learning and memory. Cold Spring Harb. Perspect. Biol. 8, a016824 (2016). (PMID: 474308210.1101/cshperspect.a016824)
Kim, Y. J. et al. STEP signaling pathway mediates psychomotor stimulation and morphine withdrawal symptoms, but not for reward, analgesia and tolerance. Exp. Mol. Med. 48, e212 (2016). (PMID: 26915673489288010.1038/emm.2016.1)
Nakayama, A., Harms, M. & Luo, L. Small GTPases Rac and Rho in the maintenance of dendritic spines and brainches in hippocampal pyramidal neurons. J. Neurosci. 20, 5329–5339 (2000). (PMID: 10884317677233410.1523/JNEUROSCI.20-14-05329.2000)

ZYM9332111 Customized Manpower Training Project funded by the National Research Council of Science & Technology; KGM5222113 KRIBB Initiative Research Program; KGS1172113 KRIBB Initiative Research Program; H-GUARD_2013M3A6B2078950 Global Frontier Project, National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT & Future Planning; NRF-2015M3C7A1029113 Brain research program, National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT & Future Planning

0 (Biomarkers)
0 (SCG2 protein, human)
0 (Secretogranin II)

Date Created: 20211124 Date Completed: 20220131 Latest Revision: 20221026

20221213

PMC8610996

10.1038/s41598-021-02262-7

34815513